



In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company,” “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 7.01 – Regulation FD Disclosure

Item 8.01 – Other Events

On March 22, 2017, the Company issued a press release reporting that the Company has repaid all of its outstanding convertible notes. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 -- Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Press release issued March 22, 2017, reporting that the Company has repaid all of its outstanding convertible notes.

SIGNATURES

Pursuant to  
the  
requirements  
of the  
Securities  
Exchange  
Act of 1934,  
the  
Registrant  
has duly  
caused this  
Report to be  
signed on its  
behalf by the  
undersigned  
hereunto duly  
authorized.

INNOVUS PHARMACEUTICALS, INC

Date: March 22, 2017 By: /s/ ROBERT E. HOFFMAN  
Robert E. Hoffman  
Executive Vice President, Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release issued March 22, 2017, reporting that the Company has repaid all of its outstanding convertible notes.